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Platinum-Taxol non-cross resistance in epithelial ovarian cancer
ME Gore, N Preston, RP A'Hern, C Hill, P Mitchell, J Chang and M Nicolson
Gynaecology Unit, The Royal Marsden Hospital, Fulhawn Road, London SW3 6JJ, UK.
Sinary The aim of this study was to assess the clinical evidence for platinum-Taxol non-cross-resistance in
patients with epitheli ovarian cancer. Unlike other studies, only patients who had demonstrably progrive
disease on platinum therapy were analysed. Patients received 135-200 mg m-2 of Taxol over 3 or 24 h and all
patients were assessed for response by computerised axial tomography. The overall response rate was 22.2%
(8/36 patients, 95% CI 10-39%). Only patients who received > 175 mg m-2 of Taxol responded (26.7%; 8/30
patients, 95% CI 12-46%). No complete responses were seen and the duration of response was short, median
7 months (range 5-9+). Response was associated with a short treatment-free interval (P=0.02); only those
who were treated immediately after they had progd on their previous platinum therapy responded.
Response duration was associated with a good performance status (P<0.05). Platinum and Taxol are
non-cross-resistant in a proportion ofpatients and therefore patients who are resistant to platinum compounds
may benefit from Taxol although the duration of any response is short These data support current strategies
that involve combining Taxol with platinum compounds as first-line therapy in advanced epithelial ovarian
cancer.
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Taxol was first isolated from the bark of the Pacific yew
(Taxus brevifolia) in 1971 (Wani et al., 1971) and has since
been shown to have a wide spectrum of biological activity
(Slichenmeyer and Von Hoff, 1991) but its main antineoplas-
tic effect appears to be the promotion of polymerisation of
microtubules, resulting in the formation of stable non-
functional microtubules (Schiff et al., 1979). The drug is
active in patients with relapsed epithelial ovarian cancer, and
cumulative data suggest that the response rate in this group
of patients is 13-50% (McGuire et al., 1989; Thigpen et al.,
1990; Enzig et al., 1992; Sarosy et al., 1992; Swenerton et al.,
1993). However, one of the most important considerations in
the design of phase II studies in relapsed ovarian cancer is
patient sekction with regard to previous treatment. It is now
well established that patients are more lily to respond to
second-line chemotherapy the longer the time interval
between the end of treatment and their relapse (Blackledge et
al., 1989; Gore et al., 1990; Markman et al., 1991). The
importance of patient seection is even greater when
evaluating whether or not a new compound is cross-resistant
to standard therapy. Trimble et al. (1993) have demonstrated
that Taxol is active in patients with poor-prognosis relapsed
epithelial ovarian cancer. Their study included patients who
had responded to platinum-based chemotherapy and relapsed
within 3 months as well as patients with truly platinum-
refractory disease, i.e. progressing while on platinum. They
did not, however, address the issue of Taxol-platinum non-
cross-resistae and its true incidence has not been studied.
Non-cross-resistance can only be confidently reported in a
population of patients that have truly platinum-refractory
disease and that can only be definitely assessed in the
presence of measurable progressive disease while the patient
is receiving platinum-based chemotherapy. We present here
our experience of Taxol given to a group of patients that
have truly platinum-refractory disease and thus report the
clinical evidence for, and incidence of, Taxol-platinum non-
cross-resistance.
Paie.ts and d
Patients
Between October 1991 and October 1993 75 patients with
refractory or relapsed epithelial ovarian cancer were entered
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into three consecutive multicentre trials of Taxol (015, 052,
005, Bristol-Myers Squibb). Thirty-six of these patients had
progressive dise as defined by UICC criteria while on
platinum therapy. These patients were therefore truly
platinum resistant and included in the analysis.
The median age of the patients was 55 years (range 27-72)
and their ECOG performance status was 0 (six patients), 1
(23 patients) or 2 (seven patients). Resistance to platinum
was documented by computerised axial tomography in 27
patients, by second-look laparotomy in four patients and by
clinical examination in conjunction with serum CA125
estimation in five patients. Patient characteristics and details
of previous treatments are set out in Tables I and II.
Patients could only enter these studies if they had his-
tologically proven epithelial ovarian cancer, ECOG status of
0-2, absolute granulocyte count < 1.5 x 1091-', platelet
count > 100 x 1091', bilirubin < 2 x upper limit of nor-
mal and creatinine S 2 x upper limit of normal. Patients
were excluded if they had serious, inadequately controlled
cardiac dise, pre-existing peripheral neuropathy >grade 2
or were known to have an allergic reaction to drugs contain-
ing Cremophor. All patients gave written informed consent
according to guidelines laid down by the Royal Marsden
Hospital Ethics Committee.
Treatment
Patients received Taxol 135 mg m2 (six patients),
175 mgm-2 (24 patients) or 200mgmr2 (six patients) intra-
venously over 3 h (33 patients) or 24 h (three patients). Taxol
was administered from a glass bottle through non-PVC lines
with an in-line filter attached. Patients were premedicated
before Taxol administration as follows: 20 mg of dex-
amethasone orally 12 and 6h before Taxol and cimetidine
300mg with chlorpheniramine 10mg intravenously 30min
before Taxol administration. Taxol was administered every
21 days.
Response assessment
Patients were assessed for response after every 2-3 cycles by
computerised axial tomography. Serum CA125 concentration
was not used for response assessment. Response was defined
according to UICC criteria: complete response (CR), com-
plete disappearance of all disease for at least 4 weeks; partial
response (PR), a decrease of 50% in the sum of the products
of the perpendicular diameter of all measured lesions without
the appearance of any new lesions for at least 4 weeks;PME GoreetalsicraP c-I ouwlin c
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Tae I Patient characteristics
No. ofpatients
Taxol
135 mgm-2
175 mgm-2
200mg M2
Age
> 55
<55
6
24
6
16
20
24
12
Histology
Serous
Non-serous
Performance status
0
1
2
Haemoglobin (g lOOml-')
>11
9.5
8-9.4
Treatment-free interval (months)
>2
<2
Number of tumour sites
<3
Maximum tumour diameter (cm)
< 5
6
23
7
24
10
2
20
16
Tablk n Treatment characterstics of 36 patients with platinum-
resistant disease treated with Taxol
No. ofpatients
Prior treatment
1 12
2 18
>,3 6
Resistant to
Single-agent platinum 30
Combination platinum therapy 6
Carboplatin 24
Cisplatin 6
Carboplatin and cisplatin 6
a trend for response to be associated with Taxol dose (0/6
responders at 135 mgm-2, 6/24 responders at 175mgm2,
2/6 responders at 200 mgm-2, P = 0.06). A longer duration
of response, as measured by the progression-free interval,
was associated with a good performance status (P = <0.05)
and there was a trend for patients with anaemia to have a
shorter progression-free interval (P = 0.07).
22
14
24
12
progressive die (PD), development of new lesions or an
increase in any measured lesion of > 25% of the products of
two perpendicular diameters; stable disease (SD), no change
in measurable lesions or changes that do not fulfil the criteria
for either PR or PD for at least 8 weeks.
Statistical methods
Exact confidence intervals on response rates are quoted.
Duration of response was measured from the date of the first
treatment to the date progression and was confirmed by
computerised axial tomography. We examined a number of
patient characteristics to assess their role as predictors of
response and response duration using log-rank analysis
(Taxol dose, histology, age, performance status, haemog-
lobin, treatment-free interval, number of disease sites, size of
largest deposit).
Redts
The overall response rate was 22.2% (8/36, 95% Ca 10-39%)
but no patient responded to 135 mg mi2 Taxol (0/6) whereas
26.7% (8/30, 95% Cl 12-46%) patients responded to
> 175mgmn2 Taxol. All patients received 1-10 cycles
(median 3) of Taxol, with responders receiving 6-10 cycles
(median 8). The median duration of response was 7 months
(range 5-9 + ). All but three patients relapsed while on
treatment; two patients developed disease progression 2 and
3 months after stopping Taxol and one patient who has just
completed treatment remains in PR at 9 + months. There
were no responses in the six patients who were resistant to
combination platinum-based chemotherapy or in the six
patients who had previously received > 3 prior treatments.
Seven patients had stabilisation of their disease lasting
1-12 +months (median 4). The median survival for all 36
patients analysed was 26 weeks (range 2-117). Response was
associated with the treatment-free interval; all responders
were in the group of patients treated immediately after pro-
gressing on platinum therapy (8/20, P = 0.02). There was also
Clinical evidence of non-cross-resistance between
chemotherapeutic agents is important to establish in order to
design more effective regimens and to help validate in vitro
chemosensitivity assays. Phase II studies can produce
misleading data in this area owing to patient selection. This
is particularly true of epithelial ovarian cancer, of which the
treatment-free interval is a powerful predictor of response in
patients who have relapsed. For instance, patients who
relapse at a disease-free interval of 1-2 years have a 27-33%
chance of responding to a rechallenge with platinum-based
chemotherapy, whereas response rates are 57-75% for
patients who relapse after 2 years (Gore et al., 1990; Mark-
man et al., 1991). A recent review of the phase II studies of
Taxol in epithelial ovarian cancer has shown that a similar
treatment-free interva-rsponse relationship probably also
exists for Taxol (Hansen et al., 1993). Trimble et al. (1993)
have shown that Taxol is active in a particularly poor-
prognosis group of patients, that is those with progressive
disease on treatment or early relapse within 3 months of their
previous therapy. However, that study does not adequately
address the issue of cross-resistance between platinum com-
pounds and Taxol because of the inclusion of this latter
group of patients. In order to assess reliably the frequency of
Taxol-platinum non-cross-resistance, it is necessary to assess
the efficacy of Taxol in patients who have progressive disease
while on platinum. Patients who had no change in tumour
measurements were not analysed in this study because the
objective measurement of disease in epithelial ovarian cancer
is notoriously inaccurate and we wanted to be absolutely sure
that the patients being assessed for Taxol-platinum non-
cross-resistance were truly platinum refractory.
Our study demonstrates that Taxol and platinum are non-
cross-resistant in 26.7% of patients when doses of
> 175 mgm2 Taxol are used. These data suggest that it is
logical to combine Taxol with platinum compounds as first-
line therapy for treatment of epithelial ovarian cancer. How-
ever, the development of Taxol resistance appears surpris-
ingly quickly. All but two of the responders relapsed while
on treatment and the median duration of response was only
7 months (range 5-9 + ). The two patients who relapsed off
treatment did so at 2 and 3 months after stopping Taxol. A
careful assessment of the symptomatic benefit that is likely to
be derived from using Taxol in a platinum-refractory patient
needs to be weighed against cost and toxicity.
All our patients were resistant to carboplatin and therefore
our data mainly relate to carboplatin-Taxol cross-resistance.
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However, we have previously shown that there is cross-
resistance between carboplatin and cisplatin in most patients
(Gore et al., 1989), and we can therefore extrapolate our data
to suggest that it is likely that Taxol and cisplatin are non-
cross-resistant in at least a proportion of patients. These data
support the current strategies exploring combinations of
Taxol and platinum compounds as first-line therapy for
advanced epithelial ovarian cancer.
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